KeyCorp Downgrades Inspire Medical Systems (NYSE:INSP) to Sector Weight

Key Points

• Inspire Medical Systems has been downgraded by KeyCorp from an "overweight" to a "sector weight" rating, indicating a shift in analyst sentiment regarding the stock's performance.
• Several analysts have revised their price targets for INSP, with Wells Fargo reducing it from $195 to $174 and Stifel Nicolaus cutting it from $190 to $175, reflecting a broader trend of decreased expectations for the stock.
• The company's recent earnings report indicated a 10.8% year-over-year revenue increase, with earnings per share significantly surpassing consensus estimates, showing strong performance despite the downgrade.

Inspire Medical Systems (NYSE:INSP - Get Free Report) was downgraded by research analysts at KeyCorp from an "overweight" rating to a "sector weight" rating in a report released on Tuesday, MarketBeat Ratings reports. KeyCorp also issued estimates for Inspire Medical Systems' Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $1.64 EPS and FY2026 earnings at $1.69 EPS.

Several other research analysts have also weighed in on the company. Stifel Nicolaus reduced their target price on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a report on Monday, April 21st. Wells Fargo & Company reduced their target price on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Robert W. Baird lifted their target price on Inspire Medical Systems from $230.00 to $236.00 and gave the stock an "outperform" rating in a report on Tuesday, May 6th. Wall Street Zen lowered Inspire Medical Systems from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. Finally, JPMorgan Chase & Co. cut their price target on Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $173.31.

Inspire Medical Systems Trading Down 1.6%

Shares of NYSE:INSP traded down $1.26 during midday trading on Tuesday, hitting $77.20. The company had a trading volume of 2,060,274 shares, compared to its average volume of 1,301,354. Inspire Medical Systems has a 12 month low of $73.92 and a 12 month high of $225.00. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of 44.62, a PEG ratio of 2.35 and a beta of 1.22. The firm has a fifty day simple moving average of $127.94 and a 200 day simple moving average of $152.62.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%. The business had revenue of $217.09 million for the quarter, compared to analyst estimates of $214.50 million. During the same period last year, the company earned $0.32 EPS. The firm's revenue was up 10.8% on a year-over-year basis. Equities analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of INSP. Dragoneer Investment Group LLC acquired a new stake in shares of Inspire Medical Systems in the fourth quarter valued at about $161,486,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Inspire Medical Systems by 214.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,112,925 shares of the company's stock worth $177,267,000 after buying an additional 759,090 shares during the last quarter. Congress Asset Management Co. increased its position in Inspire Medical Systems by 3,943.6% during the first quarter. Congress Asset Management Co. now owns 307,555 shares of the company's stock worth $48,987,000 after buying an additional 299,949 shares during the last quarter. Marshall Wace LLP increased its position in Inspire Medical Systems by 1,775.3% during the fourth quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock worth $51,375,000 after buying an additional 262,353 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Inspire Medical Systems during the fourth quarter worth approximately $47,604,000. Institutional investors and hedge funds own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.